衣原体疫苗的研究策略与进展

doi:10.3969/j.issn.1002-2694.2021.00.059

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1025 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Chlamydia is an obligatory intracellular parasite. Repeated Chlamydia infection and its severe sequelae pose a great threat to human health. Therefore, a safe and effective vaccine is urgently needed to prevent and control Chlamydia infection. Although humans have made some breakthroughs in research on the immune protection mechanism against Chlamydia and the development of vaccines, the success of potential effective Chlamydia vaccines still faces many challenges in terms of vaccine safety and effectiveness. In this paper, the factors influencing vaccine immune effects; the elements of rational design of effective Chlamydia vaccines; and the status of live attenuated vaccines, inactivated vaccines, subunit vaccines, nucleic acid vaccines, dendritic cell (DC) vaccines and bacterial ghost (BG) vaccines are briefly reviewed.

Key words： Chlamydia vaccine infection immuno-protection

Received: 21 October 2020

R374

Fund:Supported by the National Natural Science Foundation of China (No. 31570179), the Hunan Provincial Natural Science Foundation (No. 2020JJ4084), the Hunan Provincial Key Laboratory for Prevention and Control of Special Pathogens (No. 2014-5), the Hunan Provincial Cooperative Innovation Center for Molecular Target New Drug Study (No.2015-351), and the Hunan Provincial Key Discipline Project (No. 2011-76)

Corresponding Authors: Zhou Zhou, Email: susiezhou99503@163.com

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YU Nan-yan
	XIANG Wen-jing
	ZHOU Zhou

Cite this article:

YU Nan-yan,XIANG Wen-jing,ZHOU Zhou. Research strategy and progress in Chlamydia vaccines[J]. Chinese Journal of Zoonoses, 2021, 37(5): 455-461.

URL:

http://www.rsghb.cn/EN/10.3969/j.issn.1002-2694.2021.00.059 OR http://www.rsghb.cn/EN/Y2021/V37/I5/455

[1] Di Pietro M, Filardo S, Romano S, et al.Chlamydia trachomatis and Chlamydia pneumoniae interaction with the host: latest advances and future prospective[J]. Microorganisms, 2019, 7(5):140. DOI:10.3390/microorganisms7050140
[2] Ji Y, Ma XX, Li Z, et al.The burden of human papillomavirus and Chlamydia trachomatis coinfection in women: a large cohort study in Inner Mongolia, China[J]. J Infect Dis, 2019, 219(2):206-214. DOI:10.1093/infdis/jiy497
[3] Hogerwerf L, Gier B DE, Baan B, et al.Chlamydia psittaci (psittacosis) as a cause of community-acquired pneumonia: a systematic review and meta-analysis[J]. Epidemiol Infect, 2017, 145(15):3096-3105. DOI:10.1017/S0950268817002060
[4] McEntee CP, Moran HBT, Munoz-Wolf N, et al. Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming[J]. Vaccine, 2020, 38(3):635-643. DOI:10.1016/j.vaccine.2019.10.047
[5] Tang FF, Huang YT, Chang HL, et al.Isolation of trachoma virus in chick embryo[J]. J Hyg Epidemiol Microbiol Immunol, 1957, 1(2):109-120.
[6] Collier LH, Duke-Elder S, Jones BR.Experimental trachoma produced by cultured virus[J]. Br J Ophthalmol, 1958, 42(12):705-720.DOI:10.1136/bjo.42.12.705
[7] Collier LH, Duke-Elder S, Jones BR.Experimental trachoma produced by cultured virus. Part II[J]. Br J Ophthalmol, 1960, 44:65-88.DOI:10.1136/bjo.44.2.65
[8] Zheng Z, Diaz-Arevalo D, Guan H, et al.Noninvasive vaccination against infectious diseases[J]. Hum Vaccin Immunother, 2018, 14(7):1717-1733.DOI:10.1080/21645515.2018.1461296
[9] Longbottom D, Sait M, Livingstone M, et al.Genomic evidence that the live Chlamydia abortus vaccine strain 1B is not attenuated and has the potential to cause disease[J]. Vaccine, 2018, 36(25):3593-3598.DOI:10.1016/j.vaccine.2018.05.042
[10] Pais R, Omosun Y, Igietseme JU, et al.Route of vaccine administration influences the impact of fms-like tyrosine kinase 3 ligand (Flt3L) on chlamydial-specific protective immune responses[J]. Front Immunol, 2019, 10:1577.DOI:10.3389/fimmu.2019.01577
[11] Yang J, Zhang J, Han T, et al.Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2020, 99(7):e19095.DOI:10.1097/MD.0000000000019095
[12] Knudsen NP, Olsen A, Buonsanti C, et al.Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens[J]. Sci Rep, 2016, 6:19570.DOI:10.1038/srep19570
[13] Tifrea DF, Pal S, le Bon C, et al. Improved protection against Chlamydia muridarum using the native major outer membrane protein trapped in Resiquimod-carrying amphipols and effects in protection with addition of a Th1 (CpG-1826) and a Th2 (Montanide ISA 720) adjuvant[J]. Vaccine, 2020, 38(28):4412-4422.DOI:10.1016/j.vaccine.2020.04.065
[14] Fuenmayor J, Godia F, Cervera L.Production of virus-like particles for vaccines[J]. N Biotechnol, 2017, 39(Pt B):174-180.DOI:10.1016/j.nbt.2017.07.010
[15] Sharma J, Shepardson K, Johns LL, et al.A self-adjuvanted, modular, antigenic VLP for rapid response to influenza virus variability[J]. ACS Appl Mater Interfaces, 2020, 12(16):18211-18224.DOI:10.1021/acsami.9b21776
[16] Liang S, Bulir D, Kaushic C, et al.Considerations for the rational design of a Chlamydia vaccine[J]. Hum Vaccin Immunother, 2017, 13(4):831-835.DOI:10.1080/21645515.2016.1252886
[17] Kaser T, Renois F, Wilson HL, et al.Contribution of the swine model in the study of human sexually transmitted infections[J]. Infect Genet Evol, 2018, 66:346-360.DOI:10.1016/j.meegid.2017.11.022
[18] Amaral AF, Rahman KS, Kick AR, et al.Mucosal vaccination with UV-inactivated Chlamydia suis in pre-exposed outbred pigs decreases pathogen load and induces CD4 T-Cell maturation into IFN-gamma(+) effector memory cells[J]. Vaccines (Basel), 2020, 8(3) :353.DOI:10.3390/vaccines8030353
[19] Lizarraga D, Carver S, Timms P.Navigating to the most promising directions amid complex fields of vaccine development: a chlamydial case study[J]. Expert Rev Vaccines, 2019, 18(12):1323-1337.DOI:10.1080/14760584.2019.1698954
[20] Detmer A, Glenting J.Live bacterial vaccines-a review and identification of potential hazards[J]. Microb Cell Fact, 2006, 5:23.DOI:10.1186/1475-2859-5-23
[21] Grayston JT, Wang SP.The potential for vaccine against infection of the genital tract with Chlamydia trachomatis[J]. Sex Transm Dis, 1978, 5(2):73-77.DOI:10.1097/00007435-197804000-00011
[22] Kari L, Whitmire WM, Olivares-Zavaleta N, et al.A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates[J]. J Exp Med, 2011, 208(11):2217-2223.DOI:10.1084/jem.20111266
[23] 陈超群,任林,陆春雪,等. 鼠衣原体质粒缺失株生物学特性及免疫保护性研究[J]. 中国病原生物学杂志, 2018, 13(3):233-238.DOI:10.13350/j.cjpb.180305
[24] Morrison SG, Giebel AM, Toh E, et al.A genital infection-attenuated Chlamydia muridarum mutant infects the gastrointestinal tract and protects against genital tract challenge[J]. mBio, 2020,11(6):e02770-20. DOI:10.1128/mBio.02770-20
[25] Cheong HC, Lee CYQ, Cheok YY, et al.CPAF, HSP60 and MOMP antigens elicit pro-inflammatory cytokines production in the peripheral blood mononuclear cells from genital Chlamydia trachomatis-infected patients[J]. Immunobiology, 2019, 224(1):34-41.DOI:10.1016/j.imbio.2018.10.010
[26] Trim L, Fattom A, Bitko V, et al.Intranasal administration with a NanoStat (TM)(M)-MOMP vaccine reduces the incidence of oviduct pathology in Chlamydia-infected mice[J]. Eur J Immunol, 2016, 46:1230.
[27] Pal S, Tifrea DF, de la Maza LM. Characterization of the horizontal and vertical sexual transmission of Chlamydia Genital infections in a new mouse model[J]. Infect Immun, 2019, 87(7) :e00834-18. DOI:10.1128/IAI.00834-18
[28] Pal S, Cruz-Fisher MI, Cheng C, et al.Vaccination with the recombinant major outer membrane protein elicits long-term protection in mice against vaginal shedding and infertility following a Chlamydia muridarum genital challenge[J]. NPJ Vaccines, 2020, 5:90.DOI:10.1038/s41541-020-00239-7
[29] Khan SA, Polkinghorne A, Waugh C, et al.Humoral immune responses in koalas (Phascolarctos cinereus) either naturally infected with Chlamydia pecorum or following administration of a recombinant chlamydial major outer membrane protein vaccine[J]. Vaccine, 2016, 34(6):775-782. DOI:10.1016/j.vaccine.2015.12.050
[30] Tifrea DF, Pal S, de la Maza LM. A recombinant Chlamydia trachomatis MOMP vaccine elicits cross-serogroup protection in mice against vaginal shedding and infertility[J]. J Infect Dis, 2020, 221(2):191-200.DOI:10.1093/infdis/jiz438
[31] Pal S, Tifrea DF, Follmann F, et al.The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge[J]. Vaccine, 2017, 35(13):1705-1711.DOI:10.1016/j.vaccine.2017.02.020
[32] Pal S, Ausar SF, Tifrea DF, et al.Protection of outbred mice against a vaginal challenge by a Chlamydia trachomatis serovar E recombinant major outer membrane protein vaccine is dependent on phosphate substitution in the adjuvant[J]. Hum Vaccin Immunother, 2020, 16(10):2537-2547. DOI:10.1080/21645515.2020.1717183
[33] Patton MJ, McCorrister S, Grant C, et al. Chlamydial protease-like activity factor and type III secreted effectors cooperate in inhibition of p65 nuclear translocation[J]. mBio, 2016, 7(5) :e01427-16. DOI:10.1128/mBio.01427-16
[34] Li W, Gudipaty P, Li C, et al.Intranasal immunization with recombinant chlamydial protease-like activity factor attenuates atherosclerotic pathology following Chlamydia pneumoniae infection in mice[J]. Immunol Cell Biol, 2019, 97(1):85-91.DOI:10.1111/imcb.12192
[35] Wali S, Gupta R, Yu JJ, et al.Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigs[J]. Immunol Cell Biol, 2017, 95(5):454-460.DOI:10.1038/icb.2016.122
[36] Tiitinen A, Surcel HM, Halttunen M, et al.Chlamydia trachomatis and chlamydial heat shock protein 60-specific antibody and cell-mediated responses predict tubal factor infertility[J]. Hum Reprod, 2006, 21(6):1533-1538.DOI:10.1093/humrep/del014
[37] Cruz-Fisher MI, Cheng C, Sun G, et al.Identification of immunodominant antigens by probing a whole Chlamydia trachomatis open reading frame proteome microarray using sera from immunized mice[J]. Infect Immun, 2011, 79(1):246-257.DOI:10.1128/IAI.00626-10
[38] O’Neill LM, Keane OM, Ross PJ, et al. Evaluation of protective and immune responses following vaccination with recombinant MIP and CPAF from Chlamydia abortus as novel vaccines for enzootic abortion of ewes[J]. Vaccine, 2019, 37(36):5428-5438.DOI:10.1016/j.vaccine.2019.06.088
[39] Jiang PF, Cai YQ, Chen J, et al.Evaluation of tandem Chlamydia trachomatis MOMP multi-epitopes vaccine in BALB/c mice model[J]. Vaccine, 2017, 35(23):3096-3103.DOI:10.1016/j.vaccine.2017.04.031
[40] Wang C, Li Y, Wang S, et al.Evaluation of a tandem Chlamydia psittaci Pgp3 multiepitope peptide vaccine against a pulmonary chlamydial challenge in mice[J]. Microb Pathog, 2020, 147:104256. DOI:10.1016/j.micpath.2020.104256
[41] Cambridge CD, Singh SR, Waffo AB, et al.Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles[J]. Int J Nanomedicine, 2013, 8:1759-1771.DOI:10.2147/Ijn.S42723
[42] Pal S, Barnhart KM, Wei Q, et al.Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge[J]. Vaccine, 1999, 17(5):459-465.DOI:10.1016/s0264-410x(98)00219-9
[43] Vanrompay D, Cox E, Volckaert G, et al.Turkeys are protected from infection with Chlamydia psittaci by plasmid DNA vaccination against the major outer membrane protein[J]. Clin Exp Immunol, 1999, 118(1):49-55.DOI:10.1046/j.1365-2249.1999.01024.x
[44] Schautteet K, Stuyven E, Beeckman DS, et al.Protection of pigs against Chlamydia trachomatis challenge by administration of a MOMP-based DNA vaccine in the vaginal mucosa[J]. Vaccine, 2011, 29(7):1399-1407. DOI:10.1016/j.vaccine.2010.12.042
[45] Wang L, Cai Y, Xiong Y, et al.DNA plasmid vaccine carrying Chlamydia trachomatis (Ct) major outer membrane and human papillomavirus 16L2 proteins for anti-Ct infection[J]. Oncotarget, 2017, 8(20):33241-33251.DOI:10.18632/oncotarget.16601
[46] Schautteet K, De Clercq E, Vanrompay D.Chlamydia trachomatis vaccine research through the years[J]. Infect Dis Obstet Gynecol, 2011, 2011:963513.DOI:10.1155/2011/963513
[47] Gardner A, de Mingo Pulido A, Ruffell B. Dendritic cells and their role in immunotherapy[J]. Front Immunol, 2020, 11:924.DOI:10.3389/fimmu.2020.00924
[48] Cox MC, Lapenta C, Santini SM.Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma[J]. Cancer Immunol Immunother, 2020, 69(6):913-925. DOI:10.1007/s00262-020-02577-w
[49] Ashour D, Arampatzi P, Pavlovic V, et al.IL-12 from endogenous cDC1, and not vaccine DC, is required for Th1 induction[J]. JCI Insight, 2020, 5(10) :e135143.DOI:10.1172/jci.insight.135143
[50] Karunakaran KP, Yu H, Jiang X, et al.Discordance in the epithelial cell-dendritic cell major histocompatibility complex class II immunoproteome: implications for Chlamydia vaccine development[J]. J Infect Dis, 2020, 221(5):841-850.DOI:10.1093/infdis/jiz522
[51] Su H, Messer R, Whitmire W, et al.Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae[J]. J Exp Med, 1998, 188(5):809-818.DOI:10.1084/jem.188.5.809
[52] Karunakaran KP, Yu H, Jiang X, et al.Outer membrane proteins preferentially load MHC class II peptides: implications for a Chlamydia trachomatis T cell vaccine[J]. Vaccine, 2015, 33(18):2159-2166. DOI:10.1016/j.vaccine.2015.02.055
[53] Allahyari M, Mohit E.Peptide/protein vaccine delivery system based on PLGA particles[J]. Hum Vaccin Immunother, 2016, 12(3):806-828.DOI:10.1080/21645515.2015.1102804
[54] Hajam IA, Dar PA, Won G, et al.Bacterial ghosts as adjuvants: mechanisms and potential[J]. Vet Res, 2017, 48(1):37.DOI:10.1186/s13567-017-0442-5
[55] Eko FO, Talin BA, Lubitz W.Development of a Chlamydia trachomatis bacterial ghost vaccine to fight human blindness[J]. Hum Vaccin, 2008, 4(3):176-183.DOI:10.4161/hv.4.3.5393
[56] Zhou P, Wu HY, Chen SH, et al.MOMP and MIP DNA-loaded bacterial ghosts reduce the severity of lung lesions in mice after Chlamydia psittaci respiratory tract infection[J]. Immunobiology, 2019, 224(6):739-746. DOI:10.1016/j.imbio.2019.09.002
[57] Phillips S, Quigley BL, Timms P.Seventy years of Chlamydia vaccine research-limitations of the past and directions for the future[J]. Front Microbiol, 2019, 10:70.DOI:10.3389/fmicb.2019.00070